Aberdeen Group plc Sells 51,040 Shares of Hologic, Inc. $HOLX

Aberdeen Group plc decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 193,957 shares of the medical equipment provider’s stock after selling 51,040 shares during the quarter. Aberdeen Group plc owned approximately 0.09% of Hologic worth $13,090,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. increased its stake in shares of Hologic by 6.3% in the third quarter. GF Fund Management CO. LTD. now owns 6,150 shares of the medical equipment provider’s stock worth $415,000 after purchasing an additional 363 shares in the last quarter. New South Capital Management Inc. grew its stake in Hologic by 2.6% in the 3rd quarter. New South Capital Management Inc. now owns 161,865 shares of the medical equipment provider’s stock valued at $10,924,000 after buying an additional 4,030 shares in the last quarter. Public Sector Pension Investment Board grew its stake in Hologic by 15.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 19,500 shares of the medical equipment provider’s stock valued at $1,316,000 after buying an additional 2,621 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Hologic by 20.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after acquiring an additional 29,143 shares during the period. Finally, ING Groep NV purchased a new stake in shares of Hologic during the third quarter worth $1,941,000. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Morgan Stanley boosted their price objective on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Two research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, Hologic has an average rating of “Hold” and an average price target of $78.42.

Hologic Stock Performance

Hologic stock opened at $75.14 on Friday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.36. The firm has a market cap of $16.77 billion, a P/E ratio of 31.31, a P/E/G ratio of 2.24 and a beta of 0.72. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $74.91 and a 200-day moving average of $71.80.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm posted $0.87 earnings per share. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.